Arthritis Market Research Reports & Industry Analysis
Rheumatoid arthritis (RA) is a systemic inflammatory disease. In the United States, approximately a single percent of the population is affected. Women are two to three times more likely to develop rheumatoid arthritis than men, with peak incidence between the fourth and sixth decades. Gender difference disappears in older age. Rheumatoid arthritis affects all races, and its prevalence is not affected by climate. Eighty percent of rheumatoid arthritis patients test rheumatoid factor (RF) positive.
Arthritis Industry Research & Market Reports
-
Psoriatic Arthritis - Pipeline Insight, 2024
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Global Anti-Inflammatory Drugs Market - 2024-2031
... forecast period 2024-2031. Anti-inflammatory drugs, commonly referred to as anti-inflammatories or anti-inflammatory agents, are medications aimed at reducing inflammation within the body. These drugs function by inhibiting the production and activity of key inflammatory mediators, ... Read More
-
Osteoarthritis Therapeutics
... at a CAGR of 7.2% over the analysis period 2023-2030. Knee Anatomy, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$7.1 Billion by the end of ... Read More
-
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... yields glucurono-xylans, which are then sulfated to create a negatively charged substance that resembles glycosaminoglycans (GAGs). GAGs are complex carbohydrates that interact with proteins involved in inflammatory processes, thereby regulating various bodily functions. PPS is ... Read More
-
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... (OA) and rheumatoid arthritis. This novel drug is being evaluated for its effectiveness in delivering pain relief and anti-inflammatory effects directly through the skin. A Phase III clinical trial, TF-X0002-31 (Freedom-1), has been initiated at ... Read More
-
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... reducing food consumption, and lowering calorie intake. Semaglutide has received approval from the US FDA for long-term weight management in adults who are obese or overweight with at least one weight-related condition, such as hypertension, ... Read More
-
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... relief. TLC599 offers the benefit of locally delivering a powerful, clinically validated steroid that typically has a short half-life, providing both immediate and sustained effects. This emerging therapy presents several advantages, including rapid pain relief, ... Read More
-
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... It is administered through injections directly into the joint, typically every 6 to 12 months. Notably, sprifermin is the first recombinant form of FGF18 shown to promote cartilage growth in a controlled clinical trial, positioning ... Read More
-
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... Potential Vanilloid 1 (TRPV1) receptor operates through a well-established mechanism and is administered directly into the joint via intra-articular injection. As osteoarthritis patients increasingly seek effective alternatives to traditional osteoarthritis treatments, RTX-GRT7039 offers a promising ... Read More
-
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... the fetus and acting as a barrier between mother and baby. Amniotic tissue has been used in medical treatments for over a century due to its healing properties. ReNu is rich in anti-inflammatory cytokines, regenerative ... Read More
-
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... multilamellar liposomes alongside an innovative mechanism of action to deliver long-lasting symptomatic relief. Extensive pre-clinical research has confirmed the safety and lubricating effects of MM-II, which help to minimize joint friction and cartilage wear. Additionally, ... Read More
-
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... (DMOAD). Preclinical studies with vehicle-controlled models suggest that lorecivivint may act through a dual mechanism, providing three key benefits for joint health: promoting cartilage regeneration, slowing cartilage degradation, and reducing inflammation. These effects are increasingly ... Read More
-
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... This drug is being explored as a potential groundbreaking disease-modifying therapy for osteoarthritis. LNA043 is part of Novartis’s early investigational efforts aimed at addressing cartilage damage and reducing inflammation associated with osteoarthritis. This drug, which ... Read More
-
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... of hyaluronic acid and plasma protein, substances naturally present in the synovial fluid of joints, along with a fast-acting analgesic. JTA-004 aims to improve joint lubrication, protect cartilage in osteoarthritic joints, and deliver effective pain ... Read More
-
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... States and globally have demonstrated that INVOSSA can significantly relieve pain, improve mobility, and potentially slow osteoarthritis progression while enhancing joint structure. As an allogeneic, off-the-shelf therapy, it presents a promising alternative to traditional osteoarthritis ... Read More
-
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... supporting the normal function of damaged chondrocytes. This therapy for osteoarthritis also helps alleviate pain and maintain the normal structure of cartilage. By harnessing the regenerative power of stem cells, ELIXCYTE promotes tissue repair and ... Read More
-
Global Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)
... report titled “Global Immunology Biosimilars Market (2024 Edition)” which provides an analysis of the Global Immunology Biosimilars industry in terms of market segmentation By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel (Hospital ... Read More
-
Gout Therapeutics
... at a CAGR of 13.2% over the analysis period 2023-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$4.7 Billion by the end of the ... Read More
-
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... trans-capsaicin administered via injection directly to the pain site. This innovative treatment harnesses capsaicin’s natural analgesic properties, aiming to provide rapid, long-lasting, and targeted pain relief. CNTX-4975 further works by targeting the TRPV1 receptor, which ... Read More
-
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... sodium, AMZ001 stands out in the osteoarthritis medication landscape due to its targeted approach, offering effective localized pain relief with a single daily application (QD). Its targeted design helps reduce systemic exposure and minimizes the ... Read More
-
Global Stem Cell Therapy for Osteoarthritis Market 2024 by Company, Regions, Type and Application, Forecast to 2030
... progressive to joint stiffness, swelling, pain, and loss of mobility. The prevalence rate of OA is extremely high, affecting more than 250 million people worldwide. With increases in the aging and obese populations, the prevalence ... Read More
-
Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs (Nonsteroidal Anti-Inflammatory drugs), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Biologics, and Others), Type (Prescription, OTC), Route of Administration (Injectable, Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032
... Pharmacies), and Region 2024-2032 The global psoriatic arthritis treatment market size reached US$ 9.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.8 Billion by 2032, exhibiting a growth rate ... Read More
-
Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030
... projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to ... Read More
-
Non-opioid Pain Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
... a CAGR of 7.3% from 2024 to 2032. This growth can be attributed to the rising incidence of chronic pain conditions and heightened concerns over opioid addiction and its risks. With a growing number of ... Read More
-
Bone Densitometer Market Report by Device Type (Axial Bone Densitometers, Peripheral Bone Densitometers), Technology (Dual-Energy X-Ray Absorptiometry (DXA), Single X-Ray Absorptiometry (SXA), Radiographic Absorptiometry (RA), Quantitative Computed Tomography (QCT), and Others), Application (Osteoporosis and Osteopenia Diagnosis, Cystic Fibrosis Diagnosis, Body Composition Measurement, Rheumatoid Arthritis Diagnosis, and Others), End-User (Hospitals & Specialty Clinics, Diagnostics and Imaging Centers, and Others), and Region 2024-2032
... Diagnosis, Cystic Fibrosis Diagnosis, Body Composition Measurement, Rheumatoid Arthritis Diagnosis, and Others), End-User (Hospitals & Specialty Clinics, Diagnostics and Imaging Centers, and Others), and Region 2024-2032 The global bone densitometer market size reached US$ 307.6 ... Read More
Research Assistance
